Appointment of Sohanya Cheng Resignation of Michael Torok PHILADELPHIA, Oct. 30, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ:CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Sohanya Cheng, MBA to the Company's Board of Directors, effective October 31, 2024. Additionally, Michael Torok has informed the Board of his intention to step down as a member, effective October 31, 2024, due to other professional commitments. "It's a pleasure to we

PHILADELPHIA, Oct. 4, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ:CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced its upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC), taking place in Houston, Texas, November 6 -10, 2024. Details on the poster presentations at SITC 2024 are below: Title: Pre-clinical efficacy of a novel anti-GPC3 in vivo CAR-M for hepatocellular carcinoma Publication Number: 329Session Date & Time: Friday, N

Building on successful pre-clinical in vivo CAR-M data in oncology, the companies will develop in vivo CAR-M for autoimmune diseases Moderna nominated two autoimmune disease targets under the collaboration Carisma is eligible to receive milestones and royalty payments PHILADELPHIA, Sept. 10, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ:CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the expansion of its in vivo chimeric antigen receptor macrophage and monocyte (together, "CAR-M") collaboration with Moderna, Inc. (NASDAQ:MRNA) to include the nomination of two targets for

PHILADELPHIA, Sept. 3, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ:CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will participate in the following upcoming conferences: Baird 2024 Global Healthcare Conference Tuesday, September 10 at 12:50 PM ETNew York, NYH.C. Wainwright 26th Annual Global Investment Conference Wednesday, September 11 at 1:30 PM ETNew York, NYChardan's 8th Annual Genetic Medicin

Initial data for CT-0525, lead product candidate for anti-HER2 program, expected by year-end 2024 Nomination of a development candidate for liver fibrosis program expected in the first quarter of 2025 Nominated first in vivo CAR-M development candidate targeting Glypican-3 to treat hepatocellular carcinoma under the Moderna Collaboration in the second quarter of 2024 Cash and cash equivalents of $40.4 million and $2.0 million received in July under the Moderna Collaboration expected to fund the Company into the third quarter of 2025 PHILADELPHIA, Aug. 8, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ:CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focus

Company appoints renowned key opinion leaders in liver fibrosis, Scott Friedman, MD, and Ira Tabas, MD, PhD  PHILADELPHIA, Aug. 6, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ:CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Dr. Scott Friedman and Dr. Ira Tabas to its Scientific Advisory Board (SAB). Dr. Friedman and Dr. Tabas bring extensive expertise and pioneering contributions in liver fibrosis, which will be instrumental as Carisma continues its program to develop transformative treatments for patients.

PHILADELPHIA, Aug. 6, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ:CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced its upcoming poster presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024, taking place in San Diego, California, November 15 – 19, 2024. Details on the poster presentation at AASLD 2024 are below: Title: Engineered Macrophages Expressing Fibrosis-Modifying Transgenes Ameliorate Liver Fibrosis

Appointment of David Scadden, M.D. and Marella Thorell Resignation of Regina Hodits and Björn Odlander PHILADELPHIA, July 1, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ:CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Marella Thorell and David Scadden, M.D., to the Company's Board of Directors, effective June 30, 2024. Additionally, Regina Hodits and Björn Odlander have informed the Board of their intention to step down as members effective June 30, 2024, due to other professional commitments.

Development Candidate targets Glypican-3 for the treatment of solid tumors, including hepatocellular carcinoma Nomination triggers a $2 million milestone payment to Carisma PHILADELPHIA, June 27, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ:CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the nomination of the first development candidate ("Development Candidate"), under its collaboration with Moderna, Inc. The Development Candidate is an in vivo CAR-M targeting Glypican-3 ("GPC3") and is designed to treat solid tumors, including hepatocellular carcinoma ("HCC"), the most

PHILADELPHIA, June 25, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ:CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Cell Therapy Forum on Tuesday, July 9th at 9:10 am ET. An audio webcast of the event will be available on the Company's Investor Events section of the Investor Relations webpage and will be archived for a limited time following the

8-K - Carisma Therapeutics Inc. (0001485003) (Filer)

8-K - Carisma Therapeutics Inc. (0001485003) (Filer)

10-Q - Carisma Therapeutics Inc. (0001485003) (Filer)

8-K - Carisma Therapeutics Inc. (0001485003) (Filer)

8-K - Carisma Therapeutics Inc. (0001485003) (Filer)

8-K - Carisma Therapeutics Inc. (0001485003) (Filer)

8-K - Carisma Therapeutics Inc. (0001485003) (Filer)

8-K - Carisma Therapeutics Inc. (0001485003) (Filer)

8-K - Carisma Therapeutics Inc. (0001485003) (Filer)

8-K - Carisma Therapeutics Inc. (0001485003) (Filer)

SC 13D/A - Carisma Therapeutics Inc. (0001485003) (Subject)

SC 13G - Carisma Therapeutics Inc. (0001485003) (Subject)

SC 13D/A - Carisma Therapeutics Inc. (0001485003) (Subject)

BTIG Research initiated coverage of Carisma Therapeutics with a rating of Buy and set a new price target of $6.00

CapitalOne initiated coverage of Carisma Therapeutics with a rating of Overweight and set a new price target of $10.00

Evercore ISI initiated coverage of Carisma Therapeutics with a rating of Outperform and set a new price target of $12.00

Jefferies upgraded Carisma Therapeutics from Hold to Buy and set a new price target of $7.00 from $0.60 previously

H.C. Wainwright initiated coverage of Carisma Therapeutics with a rating of Buy and set a new price target of $10.00

Robert W. Baird initiated coverage of Carisma Therapeutics with a rating of Outperform and set a new price target of $10.00

Appointment of Sohanya Cheng Resignation of Michael Torok PHILADELPHIA, Oct. 30, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ:CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Sohanya Cheng, MBA to the Company's Board of Directors, effective October 31, 2024. Additionally, Michael Torok has informed the Board of his intention to step down as a member, effective October 31, 2024, due to other professional commitments. "It's a pleasure to we

Initial data for CT-0525, lead product candidate for anti-HER2 program, expected by year-end 2024 Nomination of a development candidate for liver fibrosis program expected in the first quarter of 2025 Nominated first in vivo CAR-M development candidate targeting Glypican-3 to treat hepatocellular carcinoma under the Moderna Collaboration in the second quarter of 2024 Cash and cash equivalents of $40.4 million and $2.0 million received in July under the Moderna Collaboration expected to fund the Company into the third quarter of 2025 PHILADELPHIA, Aug. 8, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ:CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focus

Company appoints renowned key opinion leaders in liver fibrosis, Scott Friedman, MD, and Ira Tabas, MD, PhD  PHILADELPHIA, Aug. 6, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ:CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Dr. Scott Friedman and Dr. Ira Tabas to its Scientific Advisory Board (SAB). Dr. Friedman and Dr. Tabas bring extensive expertise and pioneering contributions in liver fibrosis, which will be instrumental as Carisma continues its program to develop transformative treatments for patients.

Appointment of David Scadden, M.D. and Marella Thorell Resignation of Regina Hodits and Björn Odlander PHILADELPHIA, July 1, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ:CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Marella Thorell and David Scadden, M.D., to the Company's Board of Directors, effective June 30, 2024. Additionally, Regina Hodits and Björn Odlander have informed the Board of their intention to step down as members effective June 30, 2024, due to other professional commitments.

Announced CT-0525 as lead product candidate for anti-HER2 program; initial data expected by year-end 2024 Presented preclinical proof of concept data in liver fibrosis at ASGCT; expects to nominate a development candidate in the first quarter of 2025 Presented Regimen Level 1 data from Phase 1 sub-study utilizing CT-0508 in combination with pembrolizumab at AACR; expects to report Regimen Level 2 data in second quarter of 2024 Cash and cash equivalents of $56.5 million expected to fund the Company into the third quarter of 2025 PHILADELPHIA, May 9, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ:CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on

Industry veteran with expertise in oncology and immuno-oncology and a strong track record of advancing programs through clinical development PHILADELPHIA, May 2, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ:CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Eugene P. Kennedy, M.D., F.A.C.S. as the Company's Chief Medical Officer. Dr. Kennedy brings over 15 years of clinical and industry experience, including cross-functional leadership driving clinical development and regulatory strategies for oncology and immuno-oncology focused organizations. In the ro

Company to prioritize CT-0525 as its anti-HER2 CAR-M product candidate and will cease further development of CT-0508 Other prioritized pipeline programs include the Company's in vivo CAR-M collaboration with Moderna, and research programs including fibrosis Cash and cash equivalents of $77.6 million as of December 31, 2023, combined with a restructuring of operations, including pausing development of CT-1119, expected to fund the Company into the third quarter of 2025 PHILADELPHIA, April 1, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ:CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, toda

Appointment of John Hohneker, M.D. Resignation of Chidozie Ugwumba PHILADELPHIA, April 1, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ:CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of John Hohneker, M.D. to the Board of Directors of the Company, effective April 1, 2024. Additionally, the Company announced that Chidozie Ugwumba, who has served on Carisma's Board of Directors since December 2020, has advised the Board of his intent to step down from his role as a member of the Board and chair of the Audit Committee of the Board effective April 1, 2024, as

These new appointments expand the leadership team to support its legal and human resource sectors to ensure compliance and high quality employee experience PHILADELPHIA, June 14, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ:CARM) ("Carisma Therapeutics" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced leadership updates today. Eric Siegel has been appointed General Counsel and Corporate Secretary and Terry Shields has been named Senior Vice President of Human Resources. Prior to joining Carisma Therapeutics, Mr. Siegel was Chief Compliance Officer for Idorsia Pharmaceuticals US Inc. Ms. Shields

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Mark R. Sullivan, effective today, as Chief Legal Officer and Corporate Secretary. "We are very excited to welcome Mark to our management team. Mark brings tremendous legal and public company life sciences expertise and will be a strong addition to our executive team. We believe Mark's experience, insights and guidance will prove invaluable as MindMed progresses to the next stage of its evolution. I look forward to working closely with Mark during this transf

4 - Carisma Therapeutics Inc. (0001485003) (Issuer)

3 - Carisma Therapeutics Inc. (0001485003) (Issuer)

4 - Carisma Therapeutics Inc. (0001485003) (Issuer)

4 - Carisma Therapeutics Inc. (0001485003) (Issuer)

3 - Carisma Therapeutics Inc. (0001485003) (Issuer)

3 - Carisma Therapeutics Inc. (0001485003) (Issuer)

4 - Carisma Therapeutics Inc. (0001485003) (Issuer)

4 - Carisma Therapeutics Inc. (0001485003) (Issuer)

4 - Carisma Therapeutics Inc. (0001485003) (Issuer)

4 - Carisma Therapeutics Inc. (0001485003) (Issuer)

Carisma notified Novartis Pharmaceuticals of its termination of the Manufacturing and Supply Agreement, dated March 1, 2023, relating to the manufacture of the first product candidate to enter clinical development, CT-0508. The termination is effective July 31, 2024. Pursuant to the Company’s revised operating plan, the Company determined to focus its ex vivo oncology clinical development efforts on its follow-on product candidate CT-0525 and has suspended enrollment of new patients in its Phase 1 clinical trial for CT-0508. As a result of the termination of the Manufacturing Agreement, the Company will incur a termination fee equal to $4.0 million, which is expected to be paid in the thir

Carisma Therapeutics Inc. (NASDAQ:CARM) shares are trading higher on Friday following the company’s announcement of a significant development in its collaboration with Moderna. What To Know: Carisma has nominated its first in vivo CAR-M development candidate targeting Glypican-3 (GPC3) for the treatment of solid tumors, including hepatocellular carcinoma (HCC). This milestone has triggered a $2 million payment to Carisma from Moderna. The development candidate leverages Carisma’s expertise in engineering chimeric antigen receptor monocytes and macrophages (CAR-M) with Moderna’s mRNA and lipid nanoparticle platform. This collaboration aims to create novel in vivo cell therapies for onco

PTGX: 11% | Protagonist Therapeutics To Join S&P SmallCap 600, Effective Prior To Opening Of Trading On July 3 DJT: 16% | Trump Media & Technology Group shares are trading higher following Thursday's presidential debate. CARM: 95% | Carisma Therapeutics shares are trading higher after the company announced the nomination of the first in vivo CAR-M development candidate for hepatocellular carcinoma under collaboration with Moderna.

HC Wainwright & Co. analyst Mitchell Kapoor reiterates CARISMA Therapeutics (NASDAQ:CARM) with a Buy and maintains $8 price target.

Development Candidate targets Glypican-3 for the treatment of solid tumors, including hepatocellular carcinomaNomination triggers a $2 million milestone payment to CarismaPHILADELPHIA, June 27, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ:CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the nomination of the first development candidate ("Development Candidate"), under its collaboration with Moderna, Inc. The Development Candidate is an in vivo CAR-M targeting Glypican-3 ("GPC3") and is designed to treat solid tumors, including hepatocellular carcinoma ("HCC"), the most pr

5 analysts have expressed a variety of opinions on CARISMA Therapeutics (NASDAQ:CARM) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 2 0 0 0 0 3M Ago 2 0 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $7.8, a high estimate of $9.00, and a low estimate of $6.00. Obs

HC Wainwright & Co. analyst Mitchell Kapoor reiterates CARISMA Therapeutics (NASDAQ:CARM) with a Buy and maintains $8 price target.